Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BMS fills hole left by Hooper

This article was originally published in Scrip

Executive Summary

Bristol-Myers Squibb has promoted Giovanni Caforio to president of US pharmaceuticals, and Charles Bancroft and Béatrice Cazala have been appointed executive vice-presidents, both replacing Anthony Hooper, previously BMS' senior vice-president of commercial operations and president of the US, Japan/Pacific Rim and Intercontinental businesses. Mr Caforio was most recently senior vice-president of oncology and immunology global commercialisation. Mr Bancroft is currently CFO, and will add his new responsibilities to this role, while Ms Cazala will carry on her duties as the leader of global commercialisation in Europe and the emerging markets.

You may also be interested in...

Almirall launches Constella in six European markets

Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.

Dermira raises $35m in series B

Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.

Clovis ups public offering to $240m

Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts